11 min listen
ACCEL Lite: Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL-Cholesterol
FromACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
ACCEL Lite: Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL-Cholesterol
FromACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
ratings:
Length:
10 minutes
Released:
Feb 8, 2022
Format:
Podcast episode
Description
After a heart attack, levels of blood lipids such as low-density lipoprotein cholesterol (LDL-C) may influence the risk of further cardiovascular events. In this analysis, we determined that even when LDL-C levels are controlled with a statin, elevated levels of another blood lipid called lipoprotein(a) are associated with an increased risk of further cardiovascular events and a benefit of treatment with the PCSK9 inhibitors. In this interview, Gregory G. Schwartz, MD, PhD and Glenn A. Hirsch MD, MHS, FACC, with Lindsay Panah, MD, discuss Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients with Nominally Controlled LDL-Cholesterol.
Released:
Feb 8, 2022
Format:
Podcast episode
Titles in the series (100)
ACCEL Lite: STRENGTH Trial: High-Dose Omega-3 Fatty Acids vs. Corn Oil: The benefits and risks of fish oil derivatives remain controversial. STRENGTH (Long-Term Outcomes Study to Assess Statin Residual Risk With Epanova in High Cardiovascular Risk Patients With Hypertriglyceridemia) showed no benefits from administration... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research